Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC versus TRANEXAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC versus TRANEXAMIC ACID.
AMINOCAPROIC vs TRANEXAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation and, to a lesser extent, noncompetitive inhibition of plasmin, thereby preventing fibrinolysis and promoting clot stability.
Competitive inhibitor of plasminogen activation, blocking the binding of plasminogen to fibrin, thereby preventing fibrinolysis and stabilizing clots.
4-5 g orally or intravenously as a loading dose, followed by 1 g/hour continuous infusion or 1 g every 4-6 hours orally. Maximum dose 30 g/day.
1 g intravenously every 8 hours for prophylaxis of bleeding in cardiac surgery; for heavy menstrual bleeding: 1.3 g orally three times daily for up to 5 days during menstruation.
None Documented
None Documented
Clinical Note
moderateTranexamic acid + Estrone sulfate
"Tranexamic acid may increase the thrombogenic activities of Estrone sulfate."
Clinical Note
moderateTranexamic acid + Estramustine
"Tranexamic acid may increase the thrombogenic activities of Estramustine."
Clinical Note
moderateTranexamic acid + Tretinoin
"Tranexamic acid may increase the thrombogenic activities of Tretinoin."
Clinical Note
moderateAminocaproic acid + Tretinoin
Terminal elimination half-life: 2 hours (normal renal function); prolonged to 4–10 hours in renal impairment. Clinically, dosing interval must be adjusted in renal dysfunction to avoid accumulation.
Terminal elimination half-life approximately 2-11 hours (mean 2 hours in healthy adults; prolonged to 7-15 hours in renal impairment). Clinical context: dosing interval adjustment required in renal insufficiency.
Primarily renal (>95%) as unchanged drug via glomerular filtration and tubular secretion. Less than 1% biliary/fecal.
Primarily renal excretion as unchanged drug (95% within 24 hours) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category A/B
Antifibrinolytic
Antifibrinolytic
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."